ANKE BIO(SZ:300009)2022-12-08 02:18Group 1: R&D Progress - The company is currently conducting clinical trials for its main research products, including PEG-recombinant human growth hormone injection and PEG-recombinant human keratinocyte growth factor-2 (KGF-2), which is in phase III clinical trials [2] - The company is actively coordinating with clinical trial units to accelerate patient enrollment for its clinical trials [2] - The application for clinical trials of recombinant human HER-2 monoclonal antibody is nearing completion [2] - The company is also developing a series of chemical drugs, including tenofovir, in collaboration with research teams [3] Group 2: Strategic Developments - Following the acquisition of Shanghai Suhao Yiming Pharmaceutical Company, the company is focusing on the development of peptide products in oncology, gynecology, and pediatrics to enrich its product line [3] - The company is paying attention to the emerging fields of genetic testing and mobile healthcare, and plans to actively engage in these areas [3] - The company is involved in a smart healthcare project in Hefei, which will help accumulate experience in mobile healthcare [3]